[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-19-condition-pcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-19-condition-pcc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100614331","brain-stimulation-in-long-covid-100614331",false,"NCT07278206","Brain Stimulation in Long COVID","Mitigating Cognitive Problems and Fatigue With Brain Stimulation in Long COVID","MALIBU","Inclusion Criteria:\n\n* Meet the World Health Organization (WHO) definition of long COVID.\n* Aged 18 years or older.\n* Severe fatigue, defined as a score ≥35 on the Checklist Individual Strength (CIS) fatigue subscale.\n* Significant cognitive complaints, defined as a score ≥18 on the CIS concentration subscale.\n* Commitment to actively undergo rTMS\n* Ability to attend the study site regularly for treatment sessions.\n* Capacity to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior rTMS treatment or current intensive\u002Fexperimental treatment for long COVID.\n* History of epilepsy or first-degree family history of epilepsy.\n* Recent initiation or dosage change of psychotropic medication (less than six weeks for psychotropic medication including antidepressants and antipsychotic drugs, less than two weeks for benzodiazepines). Medication doses must remain stable during the study.\n* Other active concurrent pharmacological treatments for post-covid symptoms\n* Contraindications to MRI scanning (e.g., non-removable metallic implants, severe claustrophobia).\n* Presence of a cochlear implant.\n* Neurological disorders such as multiple sclerosis or other neurodegenerative conditions.\n* Pregnancy.\n* Known brain lesions or ischaemic scars influencing seizure threshold.\n* Severe uncontrolled migraines.\n* Severe cardiovascular disease\n* Raised intracranial pressure.\n* High alcohol consumption (males\u002Ffemales: 21\u002F14 units per week) or use of epileptogenic drugs.\n* Severe sleep deprivation at the time of treatment.","ALL","18 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cognitive problems and severe fatigue are two frequently occurring symptoms in long COVID, also known as Post-Covid Condition or Post-Acute Sequelae of COVID-19 (PASC), and their causes are currently unknown. Previous studies have shown reduced blood flow and increased inflammation in the brains of people with PASC. These brain processes are related to fatigue and cognitive problems. In other conditions, these disrupted brain processes have been treated safely and successfully with non-invasive brain stimulation. This may offer an effective treatment for people with PASC.\n\nThe main goal of this clinical trial is to see whether non-invasive brain stimulation called repetitive transcranial magnetic stimulation (rTMS) can reduce fatigue in adults with PASC who also have trouble concentrating. rTMS uses short magnetic pulses on the scalp to gently stimulate a small brain area.\n\nIn this study, 66 adults with PASC will be included, recruited through the Post-COVID Network Netherlands. Participants will be randomly assigned to receive either active rTMS or sham (placebo) rTMS. Sham rTMS feels and looks similar to the active treatment, but it does not generate effective magnetic pulses. The brain area that will be targeted is personalized using a brain scan (MRI) during a planning task. All participants will receive 24 rTMS sessions over six weeks (four per week).\n\nFatigue will be measured within two weeks before and two weeks after treatment to determine whether active rTMS works better than sham. We will also look at cognition, brain connectivity and blood flow, signs of (neuro)inflammation, daily activity using an activity watch, and questionnaires about quality of life, mood, and sleep. Follow-up on cognition and questionnaires will take place 3 and 6 months after the end of the treatment.",[27,28,29],"Long COVID","PASC Post Acute Sequelae of COVID 19","Post COVID-19 Condition (PCC)",[31,32,33,34,35,36,37],"TMS","PASC","long COVID","PCC","neuroimaging","non-invasive brain stimulation","transcranial magnetic stimulation","RECRUITING","2025-12-18",{"date":41,"type":42},"2025-12-19","ACTUAL",{"date":44,"type":42},"2025-11-17",{"date":46,"type":21},"2029-05-12",{"name":48,"class":49},"Amsterdam UMC, location VUmc","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100601455","effects-of-kneipp-hydrotherapy-in-post-covid-19-patients-100601455","NCT07110714","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial","HydroCoVitalB","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":60,"type":21},30,[24],"This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.",[64,29,65,66,67],"Post COVID-19 Condition","Post COVID-19","Post COVID-19 Syndrome","Long COVID-19 Syndrome",[69,70,71,72,73,74,34,33,75],"therapy","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","post COVID-19","2025-12-01",{"date":78,"type":42},"2025-12-02",{"date":76,"type":42},{"date":81,"type":21},"2027-10-31",{"name":83,"class":84},"Eggensberger OHG","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100575744","dysfunctional-breathing-in-post-covid-19-condition-100575744","NCT06776263","Dysfunctional Breathing in Post COVID-19 Condition.","Dysfunctional Breathing in Patients With Post COVID-19 Condition","DB-PCC","Inclusion Criteria:\n\n* Patients that state that they have persistent respiratory problems, have 2 or higher on mMRC scale or 23 and over on the Nijmegen scale will be included.\n\nExclusion Criteria:\n\n* Not able to perform the measurements because of cognitive or physical impairments, ongoing intervention of breathing exercises.",{"count":94,"type":21},200,"OBSERVATIONAL","The goal of this observational study with a cross-sectional design is to investigate what signs, symptoms and assessment which can describe and explain dysfunctional breathing in patients with post COVID-19 condition. The main question aims to answer which measurements can identify and asses dysfunctional breathing in patients with post COVID-19 condition?\n\nParticipants for this study will be recruited from the ReCov cohort will be evaluated with diffrent measurments and questionnaires.",[29,98,99,100],"Dysfunctional Breathing","Breathing Pattern Disorder","Post-Acute COVID-19 Syndrome",[102,103,104,105,106,107,108],"Respiration","Dyspnea","Signs and Symptoms, Respiratory","Hyperventilation","Outcome Assessment, Health Care","Patient Outcome Assessment","Surveys and Questionnaires","2025-02-13",{"date":111,"type":42},"2025-02-14",{"date":113,"type":42},"2025-01-15",{"date":115,"type":21},"2026-06-30",{"name":117,"class":49},"Karolinska Institutet",2]